• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝实质细胞特异性敲除 Pparα 在肥胖背景下促进非酒精性脂肪肝病。

Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity.

机构信息

Toxalim, INRAE UMR 1331, ENVT, INP-Purpan, University of Toulouse, Paul Sabatier University, F-31027, Toulouse, France.

Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1048, Institute of Metabolic and Cardiovascular Diseases, University of Toulouse, Paul Sabatier University, Toulouse, France.

出版信息

Sci Rep. 2020 Apr 16;10(1):6489. doi: 10.1038/s41598-020-63579-3.

DOI:10.1038/s41598-020-63579-3
PMID:32300166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7162950/
Abstract

Peroxisome proliferator activated receptor α (PPARα) acts as a fatty acid sensor to orchestrate the transcription of genes coding for rate-limiting enzymes required for lipid oxidation in hepatocytes. Mice only lacking Pparα in hepatocytes spontaneously develop steatosis without obesity in aging. Steatosis can develop into non alcoholic steatohepatitis (NASH), which may progress to irreversible damage, such as fibrosis and hepatocarcinoma. While NASH appears as a major public health concern worldwide, it remains an unmet medical need. In the current study, we investigated the role of hepatocyte PPARα in a preclinical model of steatosis. For this, we used High Fat Diet (HFD) feeding as a model of obesity in C57BL/6 J male Wild-Type mice (WT), in whole-body Pparα deficient mice (Pparα) and in mice lacking Pparα only in hepatocytes (Pparα). We provide evidence that Pparα deletion in hepatocytes promotes NAFLD and liver inflammation in mice fed a HFD. This enhanced NAFLD susceptibility occurs without development of glucose intolerance. Moreover, our data reveal that non-hepatocytic PPARα activity predominantly contributes to the metabolic response to HFD. Taken together, our data support hepatocyte PPARα as being essential to the prevention of NAFLD and that extra-hepatocyte PPARα activity contributes to whole-body lipid homeostasis.

摘要

过氧化物酶体增殖物激活受体 α (PPARα) 作为脂肪酸传感器,协调编码肝细胞中脂质氧化限速酶的基因转录。仅在肝细胞中缺乏 Pparα 的小鼠在衰老时会自发发生非肥胖性脂肪变性而不发生肥胖。脂肪变性可发展为非酒精性脂肪性肝炎 (NASH),后者可能进展为不可逆损伤,如纤维化和肝癌。虽然 NASH 似乎是全球范围内的一个主要公共卫生问题,但它仍然是一个未满足的医疗需求。在本研究中,我们研究了肝细胞 PPARα 在脂肪变性的临床前模型中的作用。为此,我们使用高脂肪饮食 (HFD) 喂养作为 C57BL/6J 雄性野生型小鼠 (WT)、全身缺乏 Pparα 的小鼠 (Pparα) 和仅缺乏肝细胞中 Pparα 的小鼠 (Pparα) 的肥胖模型。我们提供的证据表明,肝细胞中 Pparα 的缺失会促进 HFD 喂养小鼠的非酒精性脂肪性肝病和肝脏炎症。这种增强的非酒精性脂肪性肝病易感性发生而没有发展为葡萄糖不耐受。此外,我们的数据表明,非肝细胞 PPARα 活性主要有助于对 HFD 的代谢反应。总之,我们的数据支持肝细胞 PPARα 对于预防非酒精性脂肪性肝病是必不可少的,并且肝细胞外的 PPARα 活性有助于全身脂质稳态。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/9e527026fddf/41598_2020_63579_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/caee5569b118/41598_2020_63579_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/95d3240af63d/41598_2020_63579_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/7ecfcbf186ff/41598_2020_63579_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/2c3d3a9cac61/41598_2020_63579_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/5b18fb7298ac/41598_2020_63579_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/2c662c9a119e/41598_2020_63579_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/9e527026fddf/41598_2020_63579_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/caee5569b118/41598_2020_63579_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/95d3240af63d/41598_2020_63579_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/7ecfcbf186ff/41598_2020_63579_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/2c3d3a9cac61/41598_2020_63579_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/5b18fb7298ac/41598_2020_63579_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/2c662c9a119e/41598_2020_63579_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/7162950/9e527026fddf/41598_2020_63579_Fig7_HTML.jpg

相似文献

1
Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity.肝实质细胞特异性敲除 Pparα 在肥胖背景下促进非酒精性脂肪肝病。
Sci Rep. 2020 Apr 16;10(1):6489. doi: 10.1038/s41598-020-63579-3.
2
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.肝脏中的过氧化物酶体增殖物激活受体α(PPARα)对于全身脂肪酸稳态至关重要,并且对非酒精性脂肪性肝病具有保护作用。
Gut. 2016 Jul;65(7):1202-14. doi: 10.1136/gutjnl-2015-310798. Epub 2016 Feb 1.
3
Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα.在小鼠中特异性敲除肝细胞 GPS2 通过激活 PPARα 减少非酒精性脂肪性肝炎。
Nat Commun. 2019 Apr 11;10(1):1684. doi: 10.1038/s41467-019-09524-z.
4
Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions. perilipin-2 通过不同的肝细胞和肝外细胞作用机制促进肥胖和进行性脂肪性肝病的发生。
J Physiol. 2019 Mar;597(6):1565-1584. doi: 10.1113/JP277140. Epub 2019 Jan 2.
5
Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity.肝脏中过氧化物酶体增殖物激活受体α(PPARα)的缺失会促进饮食诱导肥胖中的炎症和血清高脂血症。
Am J Physiol Regul Integr Comp Physiol. 2019 Nov 1;317(5):R733-R745. doi: 10.1152/ajpregu.00153.2019. Epub 2019 Sep 4.
6
The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.全氟辛烷酸对高脂饮食诱导的小鼠非酒精性脂肪性肝病的影响。
Toxicology. 2019 Mar 15;416:1-14. doi: 10.1016/j.tox.2019.01.017. Epub 2019 Jan 31.
7
Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.Mindin/Spondin 2 通过与过氧化物酶体增殖物激活受体 α 的相互作用抑制小鼠肝脂肪变性、胰岛素抵抗和肥胖。
J Hepatol. 2014 May;60(5):1046-54. doi: 10.1016/j.jhep.2014.01.011. Epub 2014 Jan 18.
8
Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.抗坏血酸通过激活高脂肪饮食喂养的 C57BL/6J 小鼠中的过氧化物酶体增殖物激活受体 α 来抑制内脏肥胖和非酒精性脂肪性肝病。
Int J Obes (Lond). 2019 Aug;43(8):1620-1630. doi: 10.1038/s41366-018-0212-0. Epub 2018 Oct 3.
9
High-fat diet induces fibrosis in mice lacking CYP2A5 and PPARα: a new model for steatohepatitis-associated fibrosis.高脂肪饮食可诱导缺乏 CYP2A5 和 PPARα 的小鼠发生纤维化:一种与脂肪性肝炎相关纤维化相关的新型模型。
Am J Physiol Gastrointest Liver Physiol. 2020 Nov 1;319(5):G626-G635. doi: 10.1152/ajpgi.00213.2020. Epub 2020 Sep 2.
10
A novel Alisma orientale extract alleviates non-alcoholic steatohepatitis in mice via modulation of PPARα signaling pathway.一种新型的泽泻提取物通过调节 PPARα 信号通路缓解了小鼠的非酒精性脂肪性肝炎。
Biomed Pharmacother. 2024 Jul;176:116908. doi: 10.1016/j.biopha.2024.116908. Epub 2024 Jun 7.

引用本文的文献

1
Adipocyte-specific deletion of gp130 prevents ketogenic diet-induced hepatic steatosis.脂肪细胞特异性缺失gp130可预防生酮饮食诱导的肝脂肪变性。
Hepatol Commun. 2025 Aug 26;9(9). doi: 10.1097/HC9.0000000000000782. eCollection 2025 Sep 1.
2
Loss of SVIP Results in Metabolic Reprograming and Increased Retention of Very-Low-Density Lipoproteins in Hepatocytes.SVIP缺失导致肝细胞代谢重编程及极低密度脂蛋白潴留增加。
Int J Mol Sci. 2025 Aug 1;26(15):7465. doi: 10.3390/ijms26157465.
3
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease.

本文引用的文献

1
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.Metascape 为系统水平数据集的分析提供了面向生物学家的资源。
Nat Commun. 2019 Apr 3;10(1):1523. doi: 10.1038/s41467-019-09234-6.
2
Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice.肝外过氧化物酶体增殖物激活受体α调节脂肪酸氧化,减轻小鼠饥饿诱导的肝脂肪变性。
J Lipid Res. 2018 Nov;59(11):2140-2152. doi: 10.1194/jlr.M088419. Epub 2018 Aug 29.
3
Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.
代谢功能障碍相关脂肪性肝病的抗纤维化治疗
JHEP Rep. 2025 Apr 11;7(8):101421. doi: 10.1016/j.jhepr.2025.101421. eCollection 2025 Aug.
4
Somatic loss-of-function mutations in CIDEB reduce hepatic steatosis by increasing lipolysis and fatty acid oxidation.CIDEB中的体细胞功能丧失突变通过增加脂肪分解和脂肪酸氧化来减轻肝脂肪变性。
J Hepatol. 2025 Jul 4. doi: 10.1016/j.jhep.2025.06.021.
5
Deletion of PPARα in mouse brown adipocytes increases their De Novo Lipogenesis.小鼠棕色脂肪细胞中PPARα的缺失会增加其从头脂肪生成。
Mol Metab. 2025 Aug;98:102184. doi: 10.1016/j.molmet.2025.102184. Epub 2025 Jun 10.
6
Feasibility of shear wave elastography for assessing steatosis in early-stage non-alcoholic fatty liver disease.剪切波弹性成像评估早期非酒精性脂肪性肝病肝脂肪变的可行性
PLoS One. 2025 May 29;20(5):e0324637. doi: 10.1371/journal.pone.0324637. eCollection 2025.
7
PPARα regulates ER-lipid droplet protein Calsyntenin-3β to promote ketogenesis in hepatocytes.过氧化物酶体增殖物激活受体α(PPARα)调节内质网-脂滴蛋白钙黏连蛋白-3β,以促进肝细胞中的生酮作用。
Proc Natl Acad Sci U S A. 2025 Apr 29;122(17):e2426338122. doi: 10.1073/pnas.2426338122. Epub 2025 Apr 21.
8
Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization.基于生物信息学分析结合孟德尔随机化确定非酒精性脂肪性肝病的新型治疗靶点
Int J Mol Sci. 2025 Mar 29;26(7):3166. doi: 10.3390/ijms26073166.
9
Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies.代谢功能障碍相关脂肪性肝病:分子机制、临床意义及新兴治疗策略
Int J Mol Sci. 2025 Mar 25;26(7):2959. doi: 10.3390/ijms26072959.
10
Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease.氨基酸在代谢功能障碍相关脂肪性肝病中对肝脏糖异生和脂肪生成调节中的作用
Clin Mol Hepatol. 2025 Jul;31(3):771-795. doi: 10.3350/cmh.2025.0048. Epub 2025 Apr 16.
非酒精性脂肪性肝病和非酒精性脂肪性肝炎的无创性生物标志物:当前进展与未来前景。
Nat Rev Gastroenterol Hepatol. 2018 Aug;15(8):461-478. doi: 10.1038/s41575-018-0014-9.
4
Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet.成纤维细胞生长因子 21(FGF21)缺乏会促进长期肥胖饮食的小鼠发生肝细胞癌(HCC)。
Mol Metab. 2018 Jul;13:56-66. doi: 10.1016/j.molmet.2018.03.002. Epub 2018 Mar 8.
5
The Peroxisome Proliferator-Activated Receptor α is dispensable for cold-induced adipose tissue browning in mice.过氧化物酶体增殖物激活受体 α 对于小鼠冷诱导脂肪组织棕色化是可有可无的。
Mol Metab. 2018 Apr;10:39-54. doi: 10.1016/j.molmet.2018.01.023. Epub 2018 Feb 9.
6
The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis.新一代全过氧化物酶体增殖物激活受体激动剂IVA337可保护肝脏免受代谢紊乱和纤维化的影响。
Hepatol Commun. 2017 Jun 19;1(6):524-537. doi: 10.1002/hep4.1057. eCollection 2017 Aug.
7
A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response.特定的 ChREBP 和 PPARα 串扰是葡萄糖介导 FGF21 反应所必需的。
Cell Rep. 2017 Oct 10;21(2):403-416. doi: 10.1016/j.celrep.2017.09.065.
8
Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.非酒精性脂肪性肝病作为代谢和肝脏疾病的纽带。
Cell Metab. 2018 Jan 9;27(1):22-41. doi: 10.1016/j.cmet.2017.08.002. Epub 2017 Aug 31.
9
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.对非酒精性脂肪性肝病流行情况的建模显示,疾病负担呈指数级增长。
Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1.
10
Insights into the role of hepatocyte PPARα activity in response to fasting.肝细胞 PPARα 活性在应对禁食中的作用研究进展。
Mol Cell Endocrinol. 2018 Aug 15;471:75-88. doi: 10.1016/j.mce.2017.07.035. Epub 2017 Jul 31.